Valeant Pharma (VRX) Twitter Bull Throws in the Towel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
Valeant Pharma (VRX) Pares Earlier Decline
March 1, 2016 2:28 PM ESTValeant Pharma (NYSE: VRX) pared earlier declines to trade lower by only 1.3%.
Valeant Pharma (VRX) CEO Pearson to Hold Call with Analysts Today - Bloomberg
February 29, 2016 1:58 PM ESTValeant Pharma (NYSE: VRX) CEO Mike Pearson will hold a call with sell-side analysts later today after cancelling a public call earlier in the day, Bloomberg reported citing people families with the matter.
... MoreValeant shares slide on news of probe by U.S. SEC
February 29, 2016 10:42 AM ESTBy Ankur Banerjee and Carl O'Donnell
(Reuters) - Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent on Monday after the drugmaker revealed that it was under investigation by the U.S. Securities and Exchange Commission.
"Valeant confirms that it has several ongoing investigations, including investigations by the U.S. Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress," said Laurie Little, a Valeant spokeswoman.
She said the company confirmed that it "received a subpoena from the SEC in the fourth quarter of 2015 and, in the normal... More
Valeant Pharma (VRX) said not participating in UBS non-deal roadshow - Bloomberg
February 29, 2016 9:45 AM ESTValeant Pharma (NYSE: VRX) said not participating in UBS non-deal roadshow, according to Bloomberg.
... MoreTD Securities Downgrades Valeant Pharmaceuticals (VRX) to Hold
February 29, 2016 8:19 AM ESTTD Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold with a price target of $110.00 (from $155.00). The change follows news the company has withdrawn guidance.
"We are downgrading Valeant to HOLD from Buy to reflect the reduced visibility into F2016 outlook. The downgrade... More
Allergan (AGN) Gains FDA Acceptable For Filing Letter For Generic XIFAXAN ANDA
February 29, 2016 7:31 AM ESTAllergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the Company has received an Acceptable for Filing letter from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) seeking approval to market Rifaximin Tablets, 550... More
Valeant Pharma (VRX) Confirms Paragraph IV Patent Challenge of Salix's Xifaxan
February 29, 2016 6:10 AM ESTValeant Pharma (NYSE: VRX) confirms that its wholly owned subsidiary, Salix Pharmaceuticals, has received a notice letter dated February 11, 2016 from Actavis Laboratories FL, Inc. (Actavis) stating that the U.S. Food and Drug Administration (FDA) has received Actavis' Abbreviated New Drug Application (ANDA) containing a... More
Valeant Pharma (VRX) CEO Pearson Returns from Sick Leave; Results Delayed, Guidance Withdrawn
February 29, 2016 6:09 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that J. Michael Pearson returns as Valeant's chief executive officer following his recovery from severe pneumonia and other complications, effective immediately. Howard B. Schiller, Valeant's interim chief executive officer, will transition out of his current duties but will continue as a member of Valeant's Board of Directors. Robert A. Ingram has been appointed Chairman of the Board as the Company has separated the roles of Chairman and Chief Executive Officer.
"On behalf of the Board of Directors, I want to thank Howard and the other... More
Valeant CEO Pearson to return effective immediately, results delayed
February 28, 2016 9:10 PM ESTBy Caroline Humer
NEW YORK (Reuters) - Valeant Pharmaceuticals International (NYSE: VRX) said on Sunday that Chief Executive Officer Michael Pearson would return from medical leave effective immediately, and it postponed the release of fourth-quarter results planned for Monday.
Valeant was under pressure for its drug price increases when it said in late December that Pearson had been hospitalized for severe pneumonia. Weeks later, the company appointed board member and former Chief Financial Officer Howard Schiller as interim CEO, saying Pearson remained unwell.
Investors have been divided on Pearson's return, and... More
